Esperion sees significant U.S. opportunity for BPA combo, says Stifel

After meeting with Esperion’s CEO and CCO, Stifel analyst Derek Archila noted that they continue to see a significant commercial opportunity for a BPA combo in the U.S. as a second-line therapy behind generic statins in patients who require additional LDL-C lowering and as a potential first-line therapy for statin intolerant patients. He agrees with the company on the latter point, stating that key opinion leading doctors he has checked with have said they see the value proposition of the combo. Archila keeps a Buy rating and $112 price target on Esperion shares following the management meeting.

https://thefly.com/landingPageNews.php?id=2886187